Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 6:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,845 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dexamethasone/Dexamethasone acetate Clear all
Terminated Phase 2 Interventional Results available

Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases

NCT02490878
View directory record Official record
Conditions
Radionecrosis, Brain Metastases
Interventions
bevacizumab, corticosteroids, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
332
States / cities
Anchorage, Alaska • Arroyo Grande, California • Burbank, California + 198 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

NCT00890552
View directory record Official record
Conditions
Leukemia, Amyloidosis
Interventions
Lenalidomide, Melphalan, Dexamethasone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 1, 2026, 6:48 AM EDT
Completed No phase listed Observational

AVN of Weight-Bearing Joints In Patients With Hematologic Malignancies Treated With Dexamethasone Or Prednisone

NCT00719147
View directory record Official record
Conditions
Avascular Necrosis, Acute Lymphoblastic Leukemia
Interventions
MRI, Functional Status and Symptom Questionnaire
Procedure · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Results available

Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

NCT00603447
View directory record Official record
Conditions
Relapsed Multiple Myeloma
Interventions
Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
11
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tobramycin Tear Concentrations

NCT00695435
View directory record Official record
Conditions
Dry Eye
Interventions
TOBRADEX Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension, TOBREX Ophthalmic Solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 1, 2026, 6:48 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

NCT07224334
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00671034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Pharmacological Study, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 30 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 1, 2026, 6:48 AM EDT
Suspended Phase 1Phase 2 Interventional

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

NCT06232044
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Iberdomide, Belantamab Mafodotin, Dexamethasone, Echocardiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
43
States / cities
Ames, Iowa • Boone, Iowa • Fort Dodge, Iowa + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 1, 2026, 6:48 AM EDT
Terminated Not applicable Interventional Results available

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel

NCT02491411
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer
Interventions
Dexamethasone, Enzalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 4 Interventional Results available

Assessing Dextenza Insert After SMILE Procedure

NCT04380857
View directory record Official record
Conditions
Post Procedural Infection
Interventions
Dexamethasone ophthalmic insert 0.4 mg, Topical Prednisolone Acetate Ophthalmic Drops
Drug
Lead sponsor
William Wiley, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 3 Interventional

Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

NCT00093028
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-5013 (Revlimid™), bortezomib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2010 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

NCT00136084
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute
Interventions
Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
8
States / cities
Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 1, 2026, 6:48 AM EDT
Not yet recruiting Phase 4 Interventional

Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty

NCT07097493
View directory record Official record
Conditions
Knee Arthroplasty, Total
Interventions
Liposomal Bupivacaine, Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 1 Interventional

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

NCT02740985
View directory record Official record
Conditions
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
Interventions
AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
17
States / cities
Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 1 Interventional

Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus

NCT02872597
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Ipratropium, 0.9% Sodium Chloride, Albuterol, corticosteroids
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

NCT04273282
View directory record Official record
Conditions
Cataract
Interventions
Dexycu intracameral dexamethasone, Prednisolone Acetate
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Laguna Hills, California • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Not applicable Interventional Results available

Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD

NCT01090180
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Dexamethasone, Placebo (sugar pill)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 1, 2026, 6:48 AM EDT
Recruiting Phase 1Phase 2 Interventional

ATRA and Carfilzomib in Plasma Cell Myeloma Patients

NCT06536413
View directory record Official record
Conditions
Multiple Myeloma
Interventions
All-Trans Retinoic Acid (ATRA) Dose 0, All-Trans Retinoic Acid (ATRA) Dose 1
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 1, 2026, 6:48 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

NCT04302324
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions
Daratumumab SC, Clarithromycin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

NCT00833833
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Dexamethasone, Aspirin
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
14
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

NCT00054158
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, doxorubicin hydrochloride, thalidomide, vincristine sulfate
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 2 Interventional Results available

Emend for Multiple-day Emetogenic Chemotherapy

NCT00711555
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
aprepitant, ondansetron, dexamethasone
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

NCT01102426
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Plitidepsin, Dexamethasone
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
5
States / cities
Tuscaloosa, Alabama • Los Angeles, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 1, 2026, 6:48 AM EDT
Completed Phase 1 Interventional

Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00238225
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
calcitriol, dexamethasone, ketoconazole
Dietary Supplement · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 1, 2026, 6:48 AM EDT